Role of therapeutic drug monitoring of voriconazole in the treatment of invasive fungal infections

Canadian Journal of Hospital Pharmacy

Volumn 62, Issue 6, 2009, Pages 469-482

  Kuo, I Fan ^a   Ensom, Mary H H ^b,c  

^a ST PAUL S HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c British Columbia Research Institute for Children's and Women's Health   (United States)

Author keywords

Antifungal; Invasive fungal infection; Pharmacokinetics; Therapeutic drug monitoring; Voriconazole

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; VORICONAZOLE;

ALGORITHM; DECISION MAKING; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MONITORING; ENZYME SUBSTRATE; GENETIC POLYMORPHISM; HOMOZYGOSITY; HUMAN; LIVER DYSFUNCTION; MYCOSIS; REVIEW;

EID: 75249091587     PISSN: 00084123     EISSN: None     Source Type: Journal    
DOI: 10.4212/cjhp.v62i6.845     Document Type: Review

References (78)

1. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004;39(3):309-317. Errata in: Clin Infect Dis 2004:39(7):1093. Clin Infect Dis 2005;40(7):1077.
2. Baddley JW, Stroud TP, Salzman D, Pappas PG. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis 2001;32(9):1319-1324.
3. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002;34(7):909-917.
4. Enoch DA, Ludlam HA, Brown NM. Invasive fungal infections: a review of epidemiology and management options. J Med Microbiol 2006:55(Pt7):809- 818.
5. Meersseman W, Lagrou K, Maertens J, Van Wjingaerden E. Invasive aspergillosis in the intensive care unit. Clin Infect Dis 2007;45(2):205-216.
6. Ostrosky-Zeichner L, Pappas PG. Invasive candidiasis in the intensive care unit. Crit Care Med 2006;34(3):857-863.
7. Baden LR, Katz JT, Fishman JA, Koziol C, DelVechhio A, Doran M, et al. Salvage therapy with voriconazole for invasive fungal infections in patients failing or intolerant to standard antifungal therapy. Transplantation 2003:76(11):1632-1637.
8. Goodwin ML, Drew RH. Angifungal serum concentration monitoring: an update. J Antimicrob Chemother 2008;61(1):17-25.
9. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001;32(3):358-366.
10. Magill SS, Chiller TM, Warnock DW. Evolving strategies in the management of aspergillosis. Expert Opin Pharmacother 2008;9(2):193-209.
11. Dodds Ashley ES, Lewis R, Lewis JS, Martin C, Andes D. Pharmacology of systemic antifungal agents. Clin Infect Dis 2006;43:S28-S39.
12. Levêque D, Nivoix Y, Jehl F, Herbrecht R. Clinical pharmacokinetics of voriconazole. Int J Antimicrob Agents 2006;27(4):274-284.
13. VFEND® I.V. (voriconazole) for injection, VFEND® tablets (voriconazole), VFEND® (voriconazole) for oral suspension [US physician prescribing information]. New York (NY): Roerig Division of Pfizer Inc; revised 2008 Mar [cited 2008 Sep 3]. Available from: http://media.pfizer.com/files/ products/uspi-vfend.pdf
14. Scott LJ, Simpson D. Voriconazole: a review of its use in the management of invasive fungal infections. Drugs 2007;67(2):269-298.
15. Perfect JR, Marr KA, Walsh TJ, Greenberg RN, DuPont B, de laTorre-Cisneros, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003;36(9):1122-1131.
16. Walsh TJ, Aaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008;46(3):327-360.
17. Briefing document for voriconazole (oral and intravenous formulations). Prepared for submission to US Food and Drug Administration, Food and Drugs Advisory Committee. Pfizer, 2001 Oct 4 [cited 2008 Sep 3]. Available from:http://www.fda.gov/ohrms/dockets/ac/01 /briefing/3792b2-01-Pfizer.pdf
18. Smith J, Safdar N, Knasinski V, Simmons W, Bhavnani SM, Ambrose PG, et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006;50(4):1570-1572.
19. Patterson BE, Coates PE. UK-109-496, a novel, wide spectrum triazole for the treatment of fungal infections: pharmacokinetics in man [abstract F78, 126]. In: Program and Abstracts of the 35th Annual Meeting of the Infectious Diseases Society of America; 1995; San Francisco (CA).
20. Purkins L, Wood N, Ghahramani P, Greenhalgh K, Allen MJ, Kleinermans D. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother 2002;46(8):2546-2553.
21. Hariprasad SM, Mieler WF, Holz ER, Gao H, Kim JE, Chi J, et al. Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans. Arch Ophthalmol 2004;122(1):42-47.
22. Lutsar I, Roffey S, Troke P. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin Infect Dis 2003;37(5):728-732.
23. Mouas H, Lutsar I, Dupont B, Fain O, Herbrecht R, Lescure FX, et al.; Voriconazole/Bone Invasive Aspergillosis Study Group. Voriconazole for invasive bone aspergillosis: a worldwide experience of 20 cases. Clin Infect Dis 2005:40(8):1141-1147.
24. Denning DW, Ribaud P, Milpied N, Caillot D, Herbrecht R, Thiel E, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002;34(5):563-571.
25. Trifilio S, Pennick G, Pi J, Zook J, Golf M, Kaniecki K, etal. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer 2007;109(8):1532-1535.
26. Pasqualotto AC, Shah M, Wynn R, Denning DW Voriconazole plasma monitoring. Arch Dis Child 2008;93(7):578-581.
27. Boyd AE, Modi S, Howard SJ, Moore CB, Keevil BG, Denning DW Adverse reactions to voriconazole. Clin Infect Dis 2004;39(8):1241-1244.
28. Imhof A, Schaer DJ, Schanz U, Schwarz U. Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. Swiss Med Wkly 2006;136(45-46):739-742.
29. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008;46(2):201-211.
30. Lewis RE. What is the "therapeutic range" for voriconazole. Clin Infect Dis 2008;46(2):212-214.
31. Purkins L, Wood N, Kleinermans D, Greenhalgh K, Nichols D. Effect of food on the pharmacokinetics of multiple-dose oral voriconazole. Br J Clin Pharmacol 2003;56 Suppl 1:17-23.
32. Walsh TJ, Karlsson MO, Driscoll T, Arguedas AG, Adamson P, Saez-Llorens X, et al. Pharmacokinetics and safety of intravenous voriconazole in children after single-or multiple-dose administration. Antimicrob Agents Chemother 2004;48(6):2166-2172.
33. Smith J, Andes D. Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations. Ther Drug Monit 2008;30(2):167-172.
34. Hope WW, Billaud EM, Lestner J, Denning DW. Therapeutic drug monitoring for triazoles. Curr Opin Infect Dis 2008;21(6):580-586.
35. Brüggemann RJ, Donnelly JP, Aarnoutse RE, Warris A, Blijlevens N, Mouton JW, et al. Therapeutic drug monitoring of voriconazole. Ther Drug Monit 2008;30(4):403-411.
36. Howard A, Hoffman J, Sheth A. Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis. Ann Pharmacother 2008;42(12):1859-1864.
37. Ensom MHH, Davis GA, Cropp CD, Ensom RJ. Clinical pharmacokinetics in the 21st century. Does the evidence support definitive outcomes? Clin Pharmacokinet 1998;34(4):265-279.
38. Pappas PG, Andes D, Benjamin D Jr, Calandra TF, Edward JE Jr, Filer SG, et al. 2008 IDSA guidelines for invasive candidiasis [PowerPoint presentation]. Arlington (VA): Infectious Diseases Society of America; 2007 [cited 2008 Sep 3]. Available from: http://www.idsociety.org/WorkArea/downloadasset.aspx?id=7818
39. Herbrecht R, Denning DW, Patterson T, Bennett JE, Greene RE, Oestmann JW, et al.; Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347(6):408-415.
40. Sambatakou H, Dupont B, Lode H, Denning DW. Voriconazole treatment for subacure invasive and chronic pulmonary aspergillosis. Am J Med 2006;119(6):527.e17-527.e24.
41. Veroux M, Corona D, Gagliano M, Sorbello M, Macarone M, Cutuli M, et al. Voriconazole in the treatment of invasive aspergillosis in kidney transplant recipients. Transplant Proc 2007;39(6):1838-1840.
42. Schwartz S, Ruhnke M, Ribaud P, Corey L, Driscoll T, Comely OA. Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood 2005;106(8):2641-2645.
43. Camuset J, Nunes H, Dombret MC, Bergeron A, Henno P, Philippe B, et aL Treatment of chronic pulmonary aspergillosis by voriconazole in nonimmunocompromised patients. Chest 2007;131(5):1435-1441.
44. Ally R, Schürmann D, Kreisel W, Carosi G, Aguirrebengoa K, Dupont B, et al.; Esophageal Candidiasis Study Group. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 2001;33(9):1447-1454.
45. Kullberg BJ, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, Rex JH, et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005;366(9495):1435-1442.
46. Ostrosky-Zeichner L, Oude Lashof AML, Kullberg BJ, Rex JH. Voriconazole salvage treatment of invasive candidiasis. Eur J Clin Microbiol Infect Dis 2003:22(11):651-655.
47. Walsh TJ, Pappas P, Winston D, Lazarus HM, Petersen F, Raffalli J, Yanovich S, et al; National Institute of Allergy and Infectious Diseases Mycoses Study Group. Voriconazole compared wth liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002;346(4):225-234. Erratum in: N Engl J Med 2007;356(7):760.
48. Jergensen KJ, Gøtzsche PC, Johansen HK. Voriconazole versus amphotericin B in cancer patients with neutropenia. Cochrane Database Syst Rev 2006;(1):CD004707.
49. Spanakis EK, Aperis G, Mylonakis E. New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage. Clin Infect Dis 2006;43(8):1060-1068. Erratum in: Clin Infect Dis 2006;43(9):1232.
50. Walsh TJ, Lutsar I, Driscoll T, Dupont B, Roden M, Ghahramani P, et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 2002:21(3):240-248.
51. Cesaro S, Toffolutti T, Messina C, Calore E, Alaggio R, Cusinato R, et al. Safety and efficacy of caspofungin and liposomal amphotericin B, followed by voriconazole in young patients affected by refractory invasive mycosis. Eur J Haematol 2004;73(1):50-55.
52. Cesaro S, Strugo L, Alaggio R, Cecchetto G, Rigobello L, Pillon M, et al. Voriconazole for invasive aspergillosis in onchohematological patients: a single-center pediatric experience. Support Care Cancer 2003;11(11):722-727.
53. Kolve H, Lehrnbecher TH, Ehlert K, Paulussen M, Bielack S, Vormoor J, et al. Safety, tolerance and plasma concentrations of voriconazole in immunocompromised pediatric patients [abstract]. Clin Microbiol Infect 2004;10 Suppl 3:40-41.
54. Hilliard T, Edwards S, Buchdahl R, Francis J, Rosenthal M, Balfour-Lynn I, et al. Voriconazole therapy in children with cysric fibrosis. J Cyst Fibros 2005;4(4):215-220.
55. Pascual A, Nieth V, Calandra T, Bille J, Bolay S, Decosterd LA, et al. Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods. Antimicrob Agents Chemother 2007;51(1):137-143.
56. Perea S, Pennick GJ, Modak A, Fothergill AW, Sutton DA, Sheehan DJ, et al. Comparison of high-performance liquid chromatographic and microbiological methods for determination of voriconazole levels in plasma. Antimicrob Agennts Chemother 2000;44(5): 1209-1213.
57. Chhun S, Rey E, Tran A, Lortholary O, Pons G, Jullien V. Simultaneous quantification of voriconazole and posaconazole in human plasma by high-performance liquid chromatography with ultra-violet detection. J Chromatogr B Analyt Technol Biomed Life Sci 2007;852(1-2):223-228.
58. Gage R, Stopher DA. A rapid HPLC assay for voriconazole in human plasma. J Biomed Anal 1998;17(8):1449-1453.
59. Khoschsorur GA, Fruehwirth F, Zelzer S. Isocratic high-performance liquid chromatographic method with ultraviolet detection for simultaneous determination of levels of voriconazole and itraconazole and its hydroxy metabolite in human serum. Antimicrob Agents Chemother 2005;49(8):3569-3571.
60. Langman Lj, Boakye-Agyeman F. Measurement of voriconazole in serum and plasma. Clin Biochem 2007;40(18):1378-1385.
61. Péhourcq F, Jarry C, Bannwarth B. Direct injection HPLC micro method for the determination of voriconazole in plasma using an internal surface reversed-phase column. Biomed Chromatogr 2004;18(1):719-722.
62. Pennick GJ, Clark M, Sutton DA, Rinaldi MG. Development and validation of a high-performance liquid chromatography assay for voriconazole. Antimicrob Agents Chemother 2003;47(7):2348-2350.
63. Shihabi ZK. Simple assay for voriconazole in serum by HPLC. J Liq Chromatogr Relat Technol 2008;31(2):263-268.
64. Stopher DA, Gage R. Determination of a new antifungal agent, voriconazole, by multidimensional high-performance liquid chromatography with direct plasma injection onto a size-exclusion column. J Chromatogr B Biomed Sci Appl 1997;691(2):441-448.
65. Wenk M, Droll A, Krähenbühl S. Fast and reliable determination of the antifungal drug voriconazole in plasma using monolithic silica rod liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2006;832(2):313-316.
66. Egle H, Trittler R, König A, Kümmerer K. Fast, fully automated analysis of voriconazole from serum by LC-LC-ESI-MS-MS with parallel column-switching technique. J Chromatogr B Analyt Technol Biomed Life Sci 2005;814(2):361-367.
67. Keevil BG, Newman S, Lockhart S, Howard SJ, Moore CB, Denning DW Validation of an assay for voriconazole in serum samples using liquid chromatography-tandem mass spectrometry. Ther Drug Monit 2004;26(6):650-657.
68. Vogeser M, Schiel X, Spöhrer U. Quantification of voriconazole in plasma by liquid chromatography-tandem mass spectrometry. Clin Chan Lab Med 2005;43(7):730-734.
69. Tan K, Brayshaw N, Tomaszewski K, Troke P, Wood N. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol 2006;46(2):235-243.
70. Trifilio S, Ortiz R, Pennick G, Verma A, Pi J, Stosor V, et al. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2005;35(5):509-513.
71. Mikus G, Schöwel V, Drzewinska M, Rengelshausen J, Ding R, Riedel KD, et al. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir. Clin Pharmacol Ther 2006;80(2):126-135.
72. Eiden C, Peyrière H, Cociglio M, Djezzar S, Hansel S, Blayac JP, et al. Adverse effects of voriconazole: analysis of the French Pharmacovigilance Database. Ann Pharmacother 2007;41(5):755-763.
73. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, et al.; Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer; Mycoses Study Group of the National Institute of Allergy and Infectious Diseases. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002;34(1):7-14.
74. Ikeda Y, Umemura K, Kondo K, Sekiguchi K, Miyoshi S, Nakashima M. Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status. Clin Pharmacol Ther 2004;75(6):587-588.
75. Lazarus HM, Blumer JL, Yanovich S, Schlamm H, Romero A. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. J Clin Pharmacol 2002;42(4):395-402.
76. Peng LW, Lien YHH. Pharmacokinetics of single, oral-dose voriconazole in peritoneal dialysis patients. Am J Kidney Dis 2005;45(1):162-166.
77. Fuhrmann V, Schenk P, Jaeger W, Miksits M, Kneidinger N, Warszawska J, et al. Pharmacokinetics of voriconazole during continuous venovenous haemodiafiltration. J Antimicrob Chemother 2007;60(5):1085-1090.
78. Liu P, Foster G, Gandelman K, LaBadie RR, Allison MJ, Gutierrez MJ, et al. Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects. Antimicrob Agents Chemother 2007;51(10):3617-3626.